AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

BELLUS Health to Present at Jefferies Global Healthcare Conference in London

November 13, 2019 GMT

LAVAL, Quebec--(BUSINESS WIRE)--Nov 13, 2019--

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.

Presentation Details:

Event: Jefferies Global Healthcare Conference in London
Date/Time: Wednesday, November 20, 2019 at 9:20 a.m. GMT
Location: London

A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health’s website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company’s website.

About BELLUS Health

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191113005189/en/

CONTACT: Investors:

François Desjardins

Vice President, Finance

450-680-4525

fdesjardins@bellushealth.com

Solebury Trout

Chad Rubin

646-378-2947

crubin@troutgroup.com

Media:

Solebury Trout

Joshua R. Mansbach

646-378-2964

jmansbach@troutgroup.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: BELLUS Health Inc.

Copyright Business Wire 2019.

PUB: 11/13/2019 07:00 AM/DISC: 11/13/2019 07:01 AM

http://www.businesswire.com/news/home/20191113005189/en